Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)

PHASE3CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

November 10, 2005

Primary Completion Date

May 22, 2006

Study Completion Date

August 29, 2006

Conditions
Anesthesia, General
Interventions
DRUG

Sugammadex

Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered

DRUG

neostigmine

Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00451100 - Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931) | Biotech Hunter | Biotech Hunter